Bladder Cancer Market Overview
Bladder cancer originates in the tissues of the urinary bladder. It usually occurs in older adults, with nearly 9 in 10 individuals diagnosed with this cancer aged above 55 years. It is estimated that the likelihood of men developing bladder cancer in their lifetime is around 1 in 28 whereas in women, the chance is roughly 1 in 89. The increasing prevalence of bladder cancer and the growing elderly population are anticipated to aid the market growth. The rising advancements in diagnostic techniques and the introduction of targeted therapies and immunotherapies are projected to elevate the market value. Moreover, the growth in clinical trials and the rising preference for combination therapies are likely to impact the market dynamics.
Key Findings
- Recent data indicates that around 600,000 individuals were diagnosed with bladder cancer globally in 2022 and over 220,000 individuals died from this cancer. The high prevalence of bladder cancer is one of the primary factors fuelling the market growth.
- In April 2024, ImmunityBio, a clinical-stage biotechnology company focused on developing next-generation therapies, announced the approval of its combination therapy, Anktiva (interleukin-15 receptor agonist) along with Bacillus Calmette-Guérin (BCG) vaccine, by the U.S. Food and Drug Administration (FDA) for the treatment of a certain type of bladder cancer. This shift towards combination therapies is a major market trend.
- Increased funding and investment in bladder cancer research and the rise in new drug approvals are anticipated to elevate the market value in the forecast period.
Bladder Cancer Market Demand Drivers
According to the American Cancer Society, nearly 83,190 new cases of bladder cancer, comprising 63,070 men and 20,120 women, are projected to occur in the United States in 2024. Further, it is estimated that bladder cancer will be responsible for 16,840 deaths in the country, indicating the need for effective treatments that can address the unmet needs in oncology. Thus, the increasing burden of bladder cancer owing to factors such as the growing aging population and the rising exposure to carcinogens are contributing to the market demand.
Bladder Cancer Market Segmentation Analysis
The Cancer Type Segment is Poised to Witness Significant Growth in the Forecast Period
Based on the cancer type, the market segmentation includes transitional cell carcinoma, invasive bladder cancer, superficial bladder cancer, adenocarcinoma, and others. Transitional cell carcinoma or urothelial carcinoma is one of the most common types of bladder cancer, comprising more than 90% of the cases in industrialized countries. The growing demand for innovative treatments such as checkpoint inhibitors and the rising focus on combination therapies are expected to bolster the growth of this segment.
The market report also offers insights based on treatment type, end user, and region.
Bladder Cancer Market: Competitive Landscape
- In March 2024, global biopharmaceutical company Bristol Myers Squibb announced that the United States Food and Drug Administration (FDA) approved the combination therapy, including Opdivo ® (nivolumab) with Cisplatin and Gemcitabine, for the first-line treatment of unresectable or metastatic urothelial carcinoma in adult patients.
- In February 2024, Eindhoven-based Scinvivo, a developer of a medical technology platform focused on cancer diagnostics, successfully closed an investment round of Euro 4.7 million to support the launch of its Optical coherence tomography (OCT) imaging platform and advance bladder cancer diagnostics.
- Other players involved in the market include AstraZeneca, Pfizer, Inc., Novartis AG, Amgen Inc., F-Hoffmann-La Roche Ltd, GSK plc, Teva Pharmaceuticals Ltd., AbbVie Inc., and Eli Lilly and Company.
Bladder Cancer Market Analysis by Regional
United States is Set to Dominate Market Share
The market report offers insight into various geographical locations, including the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share which can be attributed to its substantial burden of bladder cancer and the high demand for advanced treatments. The presence of an advanced healthcare system and key market players in the country also support the market growth. The easy availability of immunotherapies and targeted therapies, such as checkpoint inhibitors, is likely to boost market demand in the region. Moreover, significant investment in clinical trials and robust regulatory support from the FDA are anticipated to aid market expansion.
Key Offerings of the Report
- The EMR report gives an overview of the market for bladder cancer for the time span of (2017-2023) and (2024-2032).
- The report also offers historical (2017-2023) and forecast (2024-2032) market information for the treatment type, cancer type, end user, and region of the market.
- The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.
About Us
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which is constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Contact Us
Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
